SCI时时刷

search
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies
Orexin Receptor Antagonists in the Treatment of Depression: A Leading Article Summarising Pre-clinical and Clinical Studies
The orexin (hypocretin) system comprises two neuropeptides (orexin-A and orexin-B) and two G-protein coupled receptors (th...
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Thromboembolic Risks with Concurrent Direct Oral Anticoagulants and Antiseizure Medications: A Population-Based Analysis
Drug–drug interactions between direct oral anticoagulants (DOAC) and antiseizure medications via the cytochrome P450...
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
Cell Biology of Parkin: Clues to the Development of New Therapeutics for Parkinson’s Disease
Parkinson’s disease is the second most prevalent neurodegenerative disease and contributes significantly to morbidit...
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
High-Efficacy Therapies for Treatment-Naïve Individuals with Relapsing–Remitting Multiple Sclerosis
There are > 18 distinct disease-modifying therapy (DMT) options covering 10 mechanisms of action currently...
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects
Evaluation of a Rapid Topiramate Titration Scheme for the Early Detection of Cognitive Side Effects
Topiramate (TPM) is effective for treating epilepsy, but executive dysfunction is a common side effect that could signific...
Dextromethorphan/Bupropion: First Approval
Dextromethorphan/Bupropion: First Approval
An oral, fixed-dose combination of dextromethorphan hydrobromide [an uncompetitive N-methyl-d-aspartate (NMDA) receptor an...
Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review
Clinical Effectiveness of Muscarinic Receptor-Targeted Interventions in Neuropsychiatric Disorders: A Systematic Review
For decades, treatment of mood disorders, psychoses, anxiety and dementia have been confounded by limited efficacy and hig...
The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis
The Efficacy and Safety of Anti-CD20 Antibody Treatments in Relapsing Multiple Sclerosis: A Systematic Review and Network Meta-analysis
Several large randomized controlled trials of anti-CD20 antibodies have been successfully conducted for the treatment of r...
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
The Safety of Deutetrabenazine for Chorea in Huntington Disease: An Open-Label Extension Study
Deutetrabenazine is approved in the USA, China, Australia, Israel, Brazil, and South Korea for the treatment of chorea ass...
Correction to: The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies
Correction to: The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonance Imaging Studies
The article “The Impact of Lithium on Brain Function in Bipolar Disorder: An Updated Review of Functional Magnetic Resonan...
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
Eslicarbazepine Acetate as Adjunctive Therapy for Primary Generalized Tonic-Clonic Seizures in Adults: A Prospective Observational Study
Eslicarbazepine acetate (ESL), a novel sodium channel blocker, is approved for mono and adjunctive treatment of partial ep...
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research
Targeting d-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research
In the brain, d-amino acid oxidase (DAAO) is a peroxisomal flavoenzyme. Through oxidative deamination by DAAO, d-serine, t...
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
Psychobehavioural and Cognitive Adverse Events of Anti-Seizure Medications for the Treatment of Developmental and Epileptic Encephalopathies
The developmental and epileptic encephalopathies encompass a group of rare syndromes characterised by severe drug-resistan...
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
Bruton’s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression?
In multiple sclerosis (MS) persisting disability can derive from acute relapses or, alternatively, from slow and steady de...
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Correction to: Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
The article “Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder”, written by Tina Nie and Hannah A. Blair, w...
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research
Psychotropic Drugs and Adverse Kidney Effects: A Systematic Review of the Past Decade of Research
Psychotropic drugs are a heterogenous group of treatments prescribed for many psychiatric disorders, often for long period...
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
A Research Domain Criteria (RDoC)-Guided Dashboard to Review Psilocybin Target Domains: A Systematic Review
Preliminary results from randomized controlled studies as well as identified molecular, cellular, and circuit targets of s...
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab: A Review in Neuromyelitis Optica Spectrum Disorder
Inebilizumab (Uplizna®) is a recently approved monoclonal antibody for use in adults with neuromyelitis optica spectr...
New Oral Drugs for Migraine
New Oral Drugs for Migraine
Migraine is a common and disabling neurological disorder, with several manifestations, of which pain is just one. Despite ...
Correction to: Antiseizure Drugs and Movement Disorders
Correction to: Antiseizure Drugs and Movement Disorders
Edmond J. Safra Program in Parkinson’s Disease, Morton and Gloria Shulman Movement Disorders Clinic, Toronto Western Hospi...
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
Correction: A Guideline and Checklist for Initiating and Managing Clozapine Treatment in Patients with Treatment-Resistant Schizophrenia
This article was published online on June 27, 2022. An error was subsequently identified in the article, and the following...
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability
Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Theref...
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
Onasemnogene Abeparvovec: A Review in Spinal Muscular Atrophy
Onasemnogene abeparvovec (Zolgensma®) is a gene therapy approved for the treatment of spinal muscular atrophy (SMA). ...
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval
Sodium Phenylbutyrate and Ursodoxicoltaurine: First Approval
An oral, fixed-dose coformulation of sodium phenylbutyrate and ursodoxicoltaurine (ALBRIOZA™; hereafter denoted sodi...